{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:37:55Z","timestamp":1767832675411,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health, USA","award":["U01MH107803"],"award-info":[{"award-number":["U01MH107803"]}]},{"name":"Swiss national foundation","award":["310030E-160403\/1"],"award-info":[{"award-number":["310030E-160403\/1"]}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["310030E-182872\/1"],"award-info":[{"award-number":["310030E-182872\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swiss Federal Institute of Technology Zurich"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>GluN2B containing <jats:italic>N<\/jats:italic>-methyl-<jats:italic>D<\/jats:italic>-aspartate receptors (NMDARs) play an essential role in neurotransmission and are a potential treatment target for multiple neurological and neurodegenerative diseases, including stroke, Alzheimer\u2019s disease, and Parkinson\u2019s disease. (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 was reported to be more specific and selective than (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 for the GluN2B subunits of the NMDAR based on their binding affinity to GluN2B and sigma-1 receptors. Here we report a comprehensive evaluation of (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 and (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF\u2013Me-NB1 in nonhuman primates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The radiosynthesis of (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 and (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 started from <jats:sup>18<\/jats:sup>F-fluorination of the boronic ester precursor, followed by removal of the acetyl protecting group. PET scans in two rhesus monkeys were conducted on the Focus 220 scanner. Blocking studies were performed after treatment of the animals with the GluN2B antagonist Co101,244 or the sigma-1 receptor antagonist FTC-146. One-tissue compartment (1TC) model and multilinear analysis-1 (MA1) method with arterial input function were used to obtain the regional volume of distribution (<jats:italic>V<\/jats:italic><jats:sub>T<\/jats:sub>, mL\/cm<jats:sup>3<\/jats:sup>). Occupancy values by the two blockers were obtained by the Lassen plot. Regional non-displaceable binding potential (<jats:italic>BP<\/jats:italic><jats:sub>ND<\/jats:sub>) was calculated from the corresponding baseline <jats:italic>V<\/jats:italic><jats:sub>T<\/jats:sub> and the <jats:italic>V<\/jats:italic><jats:sub>ND<\/jats:sub> derived from the occupancy plot of the Co101,244 blocking scans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>(<jats:italic>R<\/jats:italic>)- and (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 were produced in\u2009&gt;\u200999% radiochemical and enantiomeric purity, with molar activity of 224.22\u2009\u00b1\u2009161.69\u00a0MBq\/nmol at the end of synthesis (<jats:italic>n<\/jats:italic>\u2009=\u200910). Metabolism was moderate, with\u2009~\u200930% parent compound remaining for (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 and 20% for (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 at 30\u00a0min postinjection. Plasma free fraction was 1\u20132%. In brain regions, both (<jats:italic>R<\/jats:italic>)- and (<jats:italic>S<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 displayed fast uptake with slower clearance for the (<jats:italic>R<\/jats:italic>)- than (<jats:italic>S<\/jats:italic>)-enantiomer. For (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1, both the 1TC model and MA1 method gave reliable estimates of regional <jats:italic>V<\/jats:italic><jats:sub>T<\/jats:sub> values, with MA1 <jats:italic>V<\/jats:italic><jats:sub>T<\/jats:sub> (mL\/cm<jats:sup>3<\/jats:sup>) values ranging from 8.9 in the cerebellum to 12.8 in the cingulate cortex. Blocking with 0.25\u00a0mg\/kg of Co101,244 greatly reduced the uptake of (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 across all brain regions, resulting in occupancy of 77% and <jats:italic>V<\/jats:italic><jats:sub>ND<\/jats:sub> of 6.36, while 0.027\u00a0mg\/kg of FTC-146 reduced specific binding by 30%. Regional <jats:italic>BP<\/jats:italic><jats:sub>ND<\/jats:sub>, as a measure of specific binding signals, ranged from 0.40 in the cerebellum to 1.01 in the cingulate cortex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In rhesus monkeys, (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 exhibited fast kinetics and heterogeneous uptake across brain regions, while the (<jats:italic>S<\/jats:italic>)-enantiomer displayed a narrower dynamic range of uptake across regions. A Blocking study with a GluN2B antagonist indicated binding specificity. The value of <jats:italic>BP<\/jats:italic><jats:sub>ND<\/jats:sub> was\u2009&gt;\u20090.5 in most brain regions, suggesting good <jats:italic>in vivo<\/jats:italic> specific binding signals. Taken together, results from the current study demonstrated the potential of (<jats:italic>R<\/jats:italic>)-[<jats:sup>18<\/jats:sup>F]OF-Me-NB1 as a useful radiotracer for imaging the GluN2B receptors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-05698-9","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:04:01Z","timestamp":1643792641000},"page":"2153-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor"],"prefix":"10.1007","volume":"49","author":[{"given":"MingQiang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Smart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Holden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kapinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Felchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achi","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Tamagnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-6731","authenticated-orcid":false,"given":"Simon M.","family":"Ametamey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"5698_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0969-8051(95)02086-1","volume":"23","author":"X Ouyang","year":"1996","unstructured":"Ouyang X, Mukherjee J, Yang ZY. Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore. Nucl Med Biol. 1996;23:315\u201324. https:\/\/doi.org\/10.1016\/0969-8051(95)02086-1.","journal-title":"Nucl Med Biol"},{"key":"5698_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/s0969-8051(01)00293-1","volume":"29","author":"SM Ametamey","year":"2002","unstructured":"Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, et al. PET studies of [18F]memantine in healthy volunteers. Nucl Med Biol. 2002;29:227\u201331. https:\/\/doi.org\/10.1016\/s0969-8051(01)00293-1.","journal-title":"Nucl Med Biol"},{"key":"5698_CR3","doi-asserted-by":"publisher","first-page":"33853","DOI":"10.1074\/jbc.M112.395830","volume":"287","author":"HY Zhou","year":"2012","unstructured":"Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, et al. N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012;287:33853\u201364. https:\/\/doi.org\/10.1074\/jbc.M112.395830.","journal-title":"J Biol Chem"},{"key":"5698_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","volume":"42","author":"AS Salabert","year":"2015","unstructured":"Salabert AS, Fonta C, Fontan C, Adel D, Alonso M, Pestourie C, et al. Radiolabeling of [18F]fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors. Nucl Med Biol. 2015;42:643\u201353. https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.04.001.","journal-title":"Nucl Med Biol"},{"key":"5698_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","volume":"59","author":"AS Salabert","year":"2018","unstructured":"Salabert AS, Mora-Ramirez E, Beaurain M, Alonso M, Fontan C, Tahar HB, et al. Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats. Nucl Med Biol. 2018;59:1\u20138. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.003.","journal-title":"Nucl Med Biol"},{"key":"5698_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/0969-8051(93)90153-l","volume":"20","author":"K Orita","year":"1993","unstructured":"Orita K, Sasaki S, Maeda M, Hashimoto A, Nishikawa T, Yugami T, et al. Synthesis and evaluation of 1-(1-[5-(2\u2019-[18F]fluoroethyl)-2-thienyl]-cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex. Nucl Med Biol. 1993;20:865\u201373. https:\/\/doi.org\/10.1016\/0969-8051(93)90153-l.","journal-title":"Nucl Med Biol"},{"key":"5698_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/mol.112.080952","volume":"83","author":"JM Bhatt","year":"2013","unstructured":"Bhatt JM, Prakash A, Suryavanshi PS, Dravid SM. Effect of ifenprodil on GluN1\/GluN2B N-methyl-D-aspartate receptor gating. Mol Pharmacol. 2013;83:9\u201321. https:\/\/doi.org\/10.1124\/mol.112.080952.","journal-title":"Mol Pharmacol"},{"key":"5698_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/13543776.2020.1811234","volume":"30","author":"H Ahmed","year":"2020","unstructured":"Ahmed H, Haider A, Ametamey SM. N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present). Expert Opin Ther Pat. 2020;30:743\u201367. https:\/\/doi.org\/10.1080\/13543776.2020.1811234.","journal-title":"Expert Opin Ther Pat"},{"issue":"2533","key":"5698_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/07391102.2019.1635530","volume":"38","author":"R Singh","year":"2020","unstructured":"Singh R, Ganeshpurkar A, Kumar D, Kumar D, Kumar A, Singh SK. Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative in silico and molecular modeling approach. J Biomol Struct Dyn. 2020;38(2533):45. https:\/\/doi.org\/10.1080\/07391102.2019.1635530.","journal-title":"J Biomol Struct Dyn"},{"key":"5698_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/WNR.0000000000000685","volume":"27","author":"C Devadasan","year":"2016","unstructured":"Devadasan C, Starr B, Doyle KM. Effect of N1-dansylspermine and Ro25,6981 on locomotor activity in naive mice and in the reserpinized mouse model of Parkinson\u2019s disease. NeuroReport. 2016;27:1243\u20137. https:\/\/doi.org\/10.1097\/WNR.0000000000000685.","journal-title":"NeuroReport"},{"key":"5698_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s42003-019-0645-6","volume":"2","author":"JA Schreiber","year":"2019","unstructured":"Schreiber JA, Schepmann D, Frehland B, Thum S, Datunashvili M, Budde T, et al. A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors. Commun Biol. 2019;2:420. https:\/\/doi.org\/10.1038\/s42003-019-0645-6.","journal-title":"Commun Biol"},{"key":"5698_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.biopha.2018.08.062","volume":"107","author":"XS Wang","year":"2018","unstructured":"Wang XS, Zhang ZR, Zhang XR, Chen SY, Shao B, Xie CL. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson\u2019s rats. Biomed Pharmacother. 2018;107:769\u201376. https:\/\/doi.org\/10.1016\/j.biopha.2018.08.062.","journal-title":"Biomed Pharmacother"},{"key":"5698_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.nbd.2003.09.016","volume":"15","author":"AJ Mishizen-Eberz","year":"2004","unstructured":"Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1\/2A\/2B in hippocampal subregions throughout progression of Alzheimer\u2019s disease pathology. Neurobiol Dis. 2004;15:80\u201392. https:\/\/doi.org\/10.1016\/j.nbd.2003.09.016.","journal-title":"Neurobiol Dis"},{"key":"5698_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuroscience.2015.07.038","volume":"309","author":"CA Tamminga","year":"2015","unstructured":"Tamminga CA, Zukin RS. Schizophrenia: evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology. Neuroscience. 2015;309:233\u201342. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.07.038.","journal-title":"Neuroscience"},{"key":"5698_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1568026611313010005","volume":"13","author":"FS Menniti","year":"2013","unstructured":"Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem. 2013;13:26\u201354. https:\/\/doi.org\/10.2174\/1568026611313010005.","journal-title":"Curr Top Med Chem"},{"key":"5698_CR16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262427","author":"L Rischka","year":"2021","unstructured":"Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, et al. First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-[11C]Me-NB1. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.121.262427.","journal-title":"J Nucl Med"},{"key":"5698_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2174\/138955710791608299","volume":"10","author":"F Sobrio","year":"2010","unstructured":"Sobrio F, Gilbert G, Perrio C, Barre L, Debruyne D. PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Rev Med Chem. 2010;10:870\u201386. https:\/\/doi.org\/10.2174\/138955710791608299.","journal-title":"Mini Rev Med Chem"},{"key":"5698_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jpba.2010.04.014","volume":"53","author":"D Schepmann","year":"2010","unstructured":"Schepmann D, Frehland B, Lehmkuhl K, Tewes B, Wunsch B. Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors. J Pharm Biomed Anal. 2010;53:603\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2010.04.014.","journal-title":"J Pharm Biomed Anal"},{"issue":"5955\u201365","key":"5698_CR19","first-page":"20026631","volume":"22","author":"F Perin-Dureau","year":"2002","unstructured":"Perin-Dureau F, Rachline J, Neyton J, Paoletti P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci. 2002;22(5955\u201365):20026631.","journal-title":"J Neurosci"},{"key":"5698_CR20","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1016\/j.bmc.2010.09.026","volume":"18","author":"B Tewes","year":"2010","unstructured":"Tewes B, Frehland B, Schepmann D, Schmidtke KU, Winckler T, Wunsch B. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols. Bioorg Med Chem. 2010;18:8005\u201315. https:\/\/doi.org\/10.1016\/j.bmc.2010.09.026.","journal-title":"Bioorg Med Chem"},{"key":"5698_CR21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1021\/acschemneuro.8b00246","volume":"10","author":"CJ McGinnity","year":"2019","unstructured":"McGinnity CJ, Arstad E, Beck K, Brooks DJ, Coles JP, Duncan JS, et al. Comment on \u201c in vivo [18F]GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates.\u201d ACS Chem Neurosci. 2019;10:768\u201372. https:\/\/doi.org\/10.1021\/acschemneuro.8b00246.","journal-title":"ACS Chem Neurosci"},{"key":"5698_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2967\/jnumed.117.200451","volume":"59","author":"SD Kramer","year":"2018","unstructured":"Kramer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, et al. Evaluation of [11C]Me-NB1 as a potential PET radioligand for measuring GluN2B-containing NMDA receptors, drug occupancy, and receptor cross talk. J Nucl Med. 2018;59:698\u2013703. https:\/\/doi.org\/10.2967\/jnumed.117.200451.","journal-title":"J Nucl Med"},{"issue":"259","key":"5698_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.118.212134","volume":"60","author":"A Haider","year":"2019","unstructured":"Haider A, Iten I, Ahmed H, Muller Herder A, Gruber S, Kramer SD, et al. Identification and preclinical evaluation of a radiofluorinated benzazepine derivative for imaging the GluN2B Subunit of the Ionotropic NMDA. Receptor J Nucl Med. 2019;60(259):66. https:\/\/doi.org\/10.2967\/jnumed.118.212134.","journal-title":"Receptor J Nucl Med"},{"issue":"140","key":"5698_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2967\/jnumed.117.195586","volume":"59","author":"S Li","year":"2018","unstructured":"Li S, Cai Z, Zheng MQ, Holden D, Naganawa M, Lin SF, et al. Novel [18F]-Labeled kappa-opioid receptor antagonist as PET radiotracer: synthesis and in vivo evaluation of [18F]LY2459989 in nonhuman primates. J Nucl Med. 2018;59(140):6. https:\/\/doi.org\/10.2967\/jnumed.117.195586.","journal-title":"J Nucl Med"},{"issue":"1212","key":"5698_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2967\/jnumed.119.235143","volume":"61","author":"L Cai","year":"2020","unstructured":"Cai L, Liow JS, Morse CL, Telu S, Davies R, Frankland MP, et al. Evaluation of [11C]-NR2B-SMe and its enantiomers as PET radioligands for imaging the NR2B subunit within the NMDA receptor complex in rats. J Nucl Med. 2020;61(1212):20. https:\/\/doi.org\/10.2967\/jnumed.119.235143.","journal-title":"J Nucl Med"},{"key":"5698_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2967\/jnumed.112.109512","volume":"54","author":"MQ Zheng","year":"2013","unstructured":"Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, et al. Synthesis and evaluation of [11C]LY2795050 as a kappa-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med. 2013;54:455\u201363. https:\/\/doi.org\/10.2967\/jnumed.112.109512.","journal-title":"J Nucl Med"},{"key":"5698_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.neuroimage.2012.08.051","volume":"64","author":"CM Sandiego","year":"2013","unstructured":"Sandiego CM, Weinzimmer D, Carson RE. Optimization of PET-MR registrations for nonhuman primates using mutual information measures: a multi-transform method (MTM). Neuroimage. 2013;64:571\u201381. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.08.051.","journal-title":"Neuroimage"},{"key":"5698_CR28","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.WCB.0000038000.34930.4E","volume":"22","author":"M Ichise","year":"2002","unstructured":"Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271\u201381. https:\/\/doi.org\/10.1097\/01.WCB.0000038000.34930.4E.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5698_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","volume":"30","author":"VJ Cunningham","year":"2010","unstructured":"Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46\u201350. https:\/\/doi.org\/10.1038\/jcbfm.2009.190.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5698_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2174\/0929867013372328","volume":"8","author":"BK Kohl","year":"2001","unstructured":"Kohl BK, Dannhardt G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem. 2001;8:1275\u201389. https:\/\/doi.org\/10.2174\/0929867013372328.","journal-title":"Curr Med Chem"},{"key":"5698_CR31","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1021\/jm300371c","volume":"55","author":"ML James","year":"2012","unstructured":"James ML, Shen B, Zavaleta CL, Nielsen CH, Mesangeau C, Vuppala PK, et al. New positron emission tomography (PET) radioligand for imaging sigma-1 receptors in living subjects. J Med Chem. 2012;55:8272\u201382. https:\/\/doi.org\/10.1021\/jm300371c.","journal-title":"J Med Chem"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05698-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05698-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T09:02:33Z","timestamp":1734944553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05698-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5698"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05698-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PET imaging experiments were performed in rhesus monkeys (Macaca mulatta) according to a protocol approved by the Yale University Institutional Animal Care and Use Committee. All applicable international, national, and institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}